July 22, 2018

Contract (Development) Manufacturing Organizations continue to be in growth mode. There are a few big players in the market and several new entrants backed by either Corporations or Venture Capital firms, interested in the two digits growth rates. With the shift from small molecules and solid dose drugs to more complex and harder to copy large molecules typically in liquid formulations there is a run in the industry to expand the range of capabilities as well as services inorganically in order to become more attractive as end-to-end service provider to large pharmaceuticals as well as biotech’s. We just have to take a look at how the big players evolved over the last 10 years, or even just the consolidations in the last 3 years. And an increasing number of service providers ultimately can only be good for customers: consolidation, maturing competition, etc. 

As the competition grows, eventually an additional business differentiator which CDMOs could leverage to gain market share on top...

Please reload

Recent Posts

Please reload

Archive

Please reload

Tags

Please reload